Novo Nordisk to slash Wegovy, Ozempic U.S. checklist costs by as much as 50%

Novo Nordisk on Tuesday mentioned it plans to slash the month-to-month checklist costs of its standard weight problems and diabetes medication within the U.S. by as much as 50% beginning in 2027, in a bid to make the remedies extra accessible to sufferers with insurance coverage protection. 

The weight problems injection Wegovy, its new tablet counterpart, the diabetes shot Ozempic and the oral diabetes drug Rybelsus can have a brand new decrease checklist value of $675 per thirty days beginning on Jan. 1, 2027. The Wegovy medicines each at present have checklist costs of round $1,350 per thirty days, whereas the diabetes medication have checklist costs of round $1,027 per thirty days.

For the primary time, Novo mentioned its value cuts are concentrating on insured sufferers whose out-of-pocket prices are linked to checklist costs, corresponding to folks with high-deductible well being plans or coinsurance profit designs.

“Each of those affected person populations ought to, starting [in 2027], see a profit with decrease out-of-pocket burdens,” Jamey Millar, the corporate’s head of U.S. operations, informed CNBC in an interview.

He added that Novo expects enhancements in entry and uptake amongst sufferers within the industrial insurance coverage market, although the corporate is just not giving any particular expectations.

The transfer might assist Novo compete higher with Eli Lilly, which now holds the bulk share within the blockbuster GLP-1 market. Lilly’s simpler medication and earlier foray into the direct-to-consumer house have allowed it to take the lead within the house, however the firm has but to considerably decrease the U.S. checklist costs of its medicines.

It is unclear precisely how a lot industrial insured sufferers usually pay out of pocket for Novo’s medication. These sufferers could pay as little as $25 per thirty days for Novo’s medication in “solely the very best of circumstances,” Millar mentioned.

However sufferers in high-deductible plans must pay out of pocket “roughly the total checklist value of a drug till they attain that” threshold and the insurance coverage profit kicks in, he added. Millar mentioned a few of these sufferers defer remedy totally as a result of they do not wish to shoulder that expense. The variety of sufferers utilizing high-deductible plans has elevated over time as a result of trade-off of decrease premiums, he famous.

In the meantime, Millar mentioned different folks have 25% to 33% of their coinsurance linked to the checklist costs of these medication.

The Danish drugmaker has beforehand reduce the direct-to-consumer costs of Wegovy and Ozempic, which primarily profit cash-paying sufferers who typically haven’t got insurance coverage protection for the medication. 

Novo presents its medication to cash-paying sufferers for $149 to $499 per thirty days, relying on the particular product and dose. Novo and Lilly have escalated a GLP-1 pricing conflict during the last yr, particularly following the landmark “most favored nation” offers they struck with President Donald Trump in November.

The transfer additionally coincides with new, decrease Medicare costs going into impact for Novo’s weight problems and diabetes medication in 2027 following negotiations with the federal authorities beneath the Inflation Discount Act. The brand new negotiated costs for Wegovy, Ozempic and Rybelsus might be $274 per thirty days.